HIV prevention has a problem of equality. Here’s what needs to change


Michael Chancley, Director of Communications, user of PrEP4All and PrEP. “Local Data: Louisiana.” “HIV and Women: Diagnoses of HIV”, “Tables of HIV Surveillance Data. Table 3a, “Efficiency of PrEP”, “FDA Approves First Injection Treatment for HIV Prevention,” Dec. 20, 2021, “FDA Approves Second HIV Prevention Drug as Part of Ongoing Efforts to End the HIV Epidemic,” Oct. 2 In 2019, “The FDA approves Cabenuva and Vocabria for the treatment of HIV-1 infection.”

Dawn K. Smith, MD, Epidemiologist and Medical Officer, CDC. “FDA Approves First Drug to Reduce Sexual Acquisition of HIV Infection,” July 16, 2021.

Kimberly Smith, MD, Senior Vice President and Head of Research and Development, ViiV Healthcare.

Maggie Czarnogorski, Head of Innovation and Implementation Science, ViiV Healthcare.

Dora Martinez, MD, Medical Director, Westbrook Clinic, McAllen, TX. “Cameron County, TX.” “Harlingen, TX”, “McAllen, TX”, “Brownsville, TX.” “Cameron County, TX.”

Audrey Abernathy, Head of Communications and Foreign Affairs, ViiV Healthcare.

Sean Bland, JD, Senior Fellow, Infectious Diseases Initiative, O’Neill Institute for National and Global Health Law, Georgetown Law. “Long-term HIV treatment and prevention is coming: preparing for potential changes in the game.”

Melinda Stubbee, spokeswoman, ViiV Healthcare

JAMA network open: “Characterization of Pre-HIV Prophylaxis Behavior and HIV Prevalence among Adults in the United States in an Integrated Health Care System.”

Conference on Retroviruses and Opportunistic Infections: “Using and Referring PrEP: Black Partners of People Living with HIV in Partnership Services, 2019.”

AIDS and behavior: “The Impact of Patient Race on Clinical Decisions Related to Prescribing Pre-HIV Prophylaxis (PrEP): Assumptions on Sexual Risk Compensation and Implications for Access.”


Source link

Leave a Comment